HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
Publication date
2018-12
Authors
Belizna, Cristina
Pregnolato, Francesca
Abad, Sebastien
Alijotas-Reig, Jaume
Amital, Howard
Amoura, Zahir
Andreoli, Laura
Andres, Emmanuel
Aouba, Achile
Apras Bilgen, Sule
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
Keywords
Antiphospholipid syndrome, Hydroxychloroquine, Primary antiphospholipid syndrome, Secondary prevention, Taverne, Immunology and Allergy, Immunology
Citation
Belizna, C, Pregnolato, F, Abad, S, Alijotas-Reig, J, Amital, H, Amoura, Z, Andreoli, L, Andres, E, Aouba, A, Apras Bilgen, S, Arnaud, L, Bienvenu, B, Bitsadze, V, Blanco, P, Blank, M, Borghi, M O, Caligaro, A, Candrea, E, Canti, V, Chiche, L, Chretien, J M, Cohen Tervaert, J W, Damian, L, Delross, T, Dernis, E, Devreese, K, Djokovic, A, Esteve-Valverde, E, Favaro, M, Fassot, C, Ferrer-Oliveras, R, Godon, A, Hamidou, M, Hasan, M, Henrion, D, Imbert, B, Jeandel, P Y, Jeannin, P, Jego, P, Jourde-Chiche, N, Khizroeva, J, Lambotte, O, Landron, C, Latino, J O, Lazaro, E, de Leeuw, K, Le Gallou, T, Kiliç, L, Limper, M, Loufrani, L, Lubin, R, Magy-Bertrand, N, Mahe, G, Makatsariya, A, Martin, T, Muchardt, C, Nagy, G, Omarjee, L, Van Paasen, P, Pernod, G, Perrinet, F, Pïres Rosa, G, Pistorius, M A, Ruffatti, A, Said, F, Saulnier, P, Sene, D, Sentilhes, L, Shovman, O, Sibilia, J, Sinescu, C, Stanisavljevic, N, Stojanovich, L, Tam, L S, Tincani, A, Tollis, F, Udry, S, Ungeheuer, M N, Versini, M, Cervera, R & Meroni, P L 2018, 'HIBISCUS : Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome', Autoimmunity Reviews, vol. 17, no. 12, pp. 1153-1168. https://doi.org/10.1016/j.autrev.2018.05.012